Cover Image
Market Research Report
Product code 
1029809

Global Thrombocytopenia Management Market - 2021-2028

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Thrombocytopenia Management Market - 2021-2028
Published: September 27, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • ALL
  • Description
  • Table of Contents
Description

Market Overview

Thrombocytopenia is an autoimmune hematological bleeding disorder characterized by blood in urine, headaches, heavy menstrual period, spots on skin and bruises. It can also be caused in cancer medications, including chemotherapy and drug-induced medicines, and radiation therapies.

The global thrombocytopenia management market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Market Dynamics

Increasing prevalence rates for autoimmune hemolytic anemia is boosting the market growth.

Warm autoimmune hemolytic anemia (WAHA) is an autoimmune disorder characterized by the early destruction of healthy red blood cells (hemolysis). It occurs when one's immune system attacks healthy tissue. In WAHA and other types of autoimmune hemolytic anemia, red blood cells are tagged by antibodies and destroyed by other types of immune cells. It is the most common type of autoimmune hemolytic anemia.

According to the National Organization for Rare Disorders, WAHA affects approximately 1 to 3 per 100,000 people every year and can occur at any age. Usually, the red blood cells have a life span of approximately 120 days before the spleen destroys them. In patients with WAHA, the red blood cells are destroyed prematurely, and the increasing rate of new cells in the bone marrow can no longer pay for their loss. Additionally, the limited number of red blood cells may cause fatigue, weakness, a pale skin color (pallor), dizziness, palpitations, and shortness of breath (dyspnea). The treatment of WAHA includes corticosteroids and rituximab. Therefore, individuals who do not react to the usual treatment might require drugs that suppress the immune system, blood transfusions, or surgical spleen removal (splenectomy).

High cost of thrombocytopenia medications and treatment is likely to hamper the market growth.

The FDA has approved the anti-von Willebrand factor immunoglobulin fragment caplacizumab specifically indicated for treating adults with acquired thrombotic thrombocytopenic purpura (aTTP). But, with a list price of $270,000, the cost of the treatment outweighs its benefits.

In addition, treatment costs were calculated using U.S. list prices and facility costs. Researchers estimated treatment of a TTP episode would require four individual rituximab 375 mg/m2 doses, at the cost of $7,724 per dose; treatment with caplacizumab was $270,000 per episode. In addition, other associated costs accounted for in the model included the institution's costs for the number of TPE sessions ($6,000/TPE session), intensive care unit length of stay ($1,043/day), and total hospital length of stay ($490/day).

COVID-19 Impact Analysis

COVID-19 pandemic has moderately impacted the healthcare industry. Patients with COVID-19 pneumonia exhibit coagulation abnormalities, most commonly elevated levels of fibrinogen and D-dimer, often with mild thrombocytopenia and appear to have increased platelet consumption, together with a corresponding increase in platelet production. Disseminated intravascular coagulopathy (DIC) and severe bleeding events are uncommon in COVID-19 patients. Moreover, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Idiopathic Thrombocytopenic segment is expected to hold the largest market share in this market segment.

The idiopathic thrombocytopenic segment is held the largest market share in 2020. The segment growth is benefited due to the increasing prevalence of idiopathic thrombocytopenic purpura. For instance, according to the Mayoclinic, idiopathic thrombocytopenic purpura is a disorder that can lead to excessive bruising and bleeding. The bleeding results from especially low levels of platelets - the cells that help blood clot. Children may develop ITP after a viral infection and usually recover fully without treatment. In adults, the disorder is often long-term. For instance, according to the National Organization for Rare Disorders, The incidence of ITP and is more common over the age of 60 and increases with age. Among adults (age 30-60) diagnosed with chronic ITP, there are 2.6 cases amongst women for every case involving a male.

Moreover, in older adults, about the same number of men and women are diagnosed with ITP, whereas among children diagnosed with acute ITP, the male to female ratio is almost equal, with 52% male to 48% female. About 40% of all patients diagnosed with one or another form of ITP are children younger than ten years. Therefore, among children, the incidence is greatest between 2 and 4 years of age. However, ITP can occur at any age from 3 months to over 100 years of age.

Geographical Analysis

North America region holds the largest market share in the global thrombocytopenia management market

North America dominated the market in 2020, owing to the rising thrombocytopenia cases, favorable government initiatives and high research funding in the region is expected to boost the market in the forecast period. For instance, according to the Annals of Blood, published on March 2021, Immune thrombocytopenia (ITP) is a rare heterogeneous autoimmune bleeding disorder that makes a lower than normal circulating platelet count caused by impaired platelet production and accelerated platelet destruction.

Patients with ITP face a set of challenges. The multifaceted burden of living with ITP impacts patients and their families' overall health-related quality of life (HRQoL). Moreover, ITP leads to fatigue, challenges with daily activities, reduced physical functioning, anxiety, and depression. Aside from the constant risk for serious bleeding, patients experience physical and emotional consequences living with their disease daily. Additionally, ITP is primarily chronic in adults, with a higher prevalence in women than in men. The prevalence of ITP is 20.3 per 100,000 persons in the United States of America (USA). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

The thrombocytopenia management market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Amarillo Biosciences, Baxalta, Bayer, BioLineRx, Boehringer Ingelheim, Bolder Biotechnology, Bristol-Myers Squibb , Cellerant Therapeutics, Eisai and Genosco. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the thrombocytopenia management market globally.

Key Companies to Watch

Amgen Inc.:

Overview:

Amgen Inc. (Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company focused on molecular biology and biochemistry. The company focuses on therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Moreover, the company has a presence in around 100 countries and regions worldwide. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in cancer chemotherapy patients and Enbrel, a tumor necrosis factor blocker used to treat rheumatoid arthritis autoimmune diseases.

Product Portfolio:

Amgen Inc. has continuously set new standards for manufacturing products, including Nplate (romiplostim).

Why Purchase the Report?

  • Visualize the composition of the thrombocytopenia management market segmentation by disease type, end user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in thrombocytopenia management market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of thrombocytopenia management market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global thrombocytopenia management market report would provide an access to an approx. 50 market data table, 41 figures and 180pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Thrombocytopenia Management Market - By Disease type

  • Idiopathic Thrombocytopenic
  • Thrombotic Thrombocytopenic
  • Drug-induced Thrombocytopenia

Global Thrombocytopenia Management Market - By End user

  • Hospitals
  • Specialty Clinics
  • Ambulatory surgical centers

Global Thrombocytopenia Management Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Table of Contents
Product Code: DMPH4047

Table of Contents

1. Global Thrombocytopenia Management Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Thrombocytopenia Management Market - Market Definition and Overview

3. Global Thrombocytopenia Management Market - Executive Summary

  • 3.1. Market Snippet by Disease type
  • 3.2. Market Snippet by End user
  • 3.3. Market Snippet by Region

4. Global Thrombocytopenia Management Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in prevalence rates for autoimmune hemolytic anemia
      • 4.1.1.2. Growing awareness and disposable income of thrombocytopenia management
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of thrombocytopenia medications and treatment is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Thrombocytopenia Management Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Thrombocytopenia Management Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Thrombocytopenia Management Market - By Disease type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
    • 7.1.2. Market Attractiveness Index, By Disease type Segment
  • 7.2. Idiopathic Thrombocytopenic*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Thrombotic Thrombocytopenic
  • 7.4. Drug-induced Thrombocytopenia

8. Global Thrombocytopenia Management Market - By End user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 8.1.2. Market Attractiveness Index, By End user Segment
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Specialty Clinics
  • 8.4. Ambulatory surgical centers

9. Global Thrombocytopenia Management Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Global Thrombocytopenia Management Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. List of Key Companies to Watch
  • 10.5. List of Company with disruptive technology
  • 10.6. List of Start Up Companies

11. Global Thrombocytopenia Management Market- Company Profiles

  • 11.1. Amgen Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Amarillo Biosciences
  • 11.3. Baxalta
  • 11.4. Bayer
  • 11.5. BioLineRx
  • 11.6. Boehringer Ingelheim
  • 11.7. Bolder Biotechnology
  • 11.8. Bristol-Myers Squibb
  • 11.9. Cellerant Therapeutics
  • 11.10. Eisai
  • 11.11. Genosco

LIST NOT EXHAUSTIVE

12. Global Thrombocytopenia Management Market - DataM

  • 12.1. Appendix
  • 12.2. About Us
  • 12.3. Contact Us